Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioray Biotech CoROCO:7561 -9.19%86 EV-to-EBITDA is 9.62 as of Sep. 21, 2026, which is 75% below its 10-year median of 37.82. GuruFocus rates ROCO:7561 with a GF Score™ of 86/100 and a GF Value™ of NT$24.39 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 745 Drug Manufacturers companies, Bioray Biotech Co ranks better than 61.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bioray Biotech Co's enterprise value is NT$460.9 Mil.
Bioray Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$47.9 Mil. Therefore, Bioray Biotech Co's EV-to-EBITDA for today is 9.62.
The historical rank and industry rank for Bioray Biotech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:7561'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.99 Med: 37.82 Max: 84.22
Current: 9.62
During the past 9 years, the highest EV-to-EBITDA of Bioray Biotech Co was 84.22. The lowest was 4.99. And the median was 37.82.
ROCO:7561's EV-to-EBITDA is ranked better than 61.88% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs ROCO:7561: 9.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bioray Biotech Co (ROCO:7561) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioray Biotech Co's PE Ratio (TTM) for today is calculated as:
Bioray Biotech Co's share price for today is NT$20.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.648.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bioray Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's EV-to-EBITDA falls into.
Bioray Biotech Co's current Enterprise Value is NT$460.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$47.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a EV-to-EBITDA of 9.62 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bioray Biotech Co. This is 75% below median its historical median of 37.82. Over the past decade, Bioray Biotech Co's EV-to-EBITDA has ranged from 4.99 to 84.22. According to the industry distribution chart, Bioray Biotech Co ranks #284 out of 745 companies in the Drug Manufacturers industry, placing it in the top 38.1%.
Is Bioray Biotech Co's EV-to-EBITDA too high?
Bioray Biotech Co's current EV-to-EBITDA of 9.62 is 75% below median its 10-year median of 37.82. Over the past 10 years, this metric has ranged from a low of 4.99 to a high of 84.22. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Bioray Biotech Co's value of 9.62 is 23.4% below this industry median. Based on the distribution chart, Bioray Biotech Co ranks #284 out of 745 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bioray Biotech Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #284 out of 745 companies for EV-to-EBITDA. This puts Bioray Biotech Co in the upper half of its industry. The industry median EV-to-EBITDA is 12.56. Bioray Biotech Co's value of 9.62 is 23.4% below this benchmark. Historically, Bioray Biotech Co's own EV-to-EBITDA has ranged from 4.99 to 84.22 over the past decade. While the company's 10-year median is 37.82 vs. the industry median of 12.56, Bioray Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current EV-to-EBITDA of 9.62 is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bioray Biotech Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current EV-to-EBITDA is 9.62, which is 75% below median its own 10-year median of 37.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$24.39, compared to a current price of NT$20.25 — trading 17% below its estimated fair value. The current EV-to-EBITDA is 9.62, which is 75% below median its 10-year median of 37.82 and 23.4% below the Drug Manufacturers industry median of 12.56. Bioray Biotech Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current EV-to-EBITDA is 9.62 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$20.25 is trading 17% below its estimated GF Value™ of NT$24.39.
GuruFocus considers Bioray Biotech Co to be Modestly Undervalued.
Key valuation signals for ROCO:7561:
EV-to-EBITDA: 9.62 (75% below median its 10-year median of 37.82)
GF Value™: NT$24.39 vs. price of NT$20.25 (17% below fair value)
Industry Position: 23.4% below the Drug Manufacturers median (#284 of 745)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
86GF Score
Get the complete analysis for ROCO:7561
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
